VS-6766

Verastem Oncology announces preliminary data from investigator-initiated study highlighting clinical activity of RAF/MEK and FAK combination in KRAS mutant tumors
Pharmaceutical Business Review
Mon, 04/27/20 - 09:34 am
Verastem
clinical trials
VS-6766
solid tumors
AACR